Loading
A phase 2/3 trial testing EIK1001 in non-small-cell lung cancer, now recruiting.
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT07365319, led by Eikon Therapeutics with Merck Sharp & Dohme, and recruiting on the registry. Official title: A Global, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008). Planned enrolment is 750 participants (estimated). The study started in 2026-06-15 and primary completion is expected in 2035-12-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares EIK1001, Eikon Therapeutics.
Shares EIK1001, Eikon Therapeutics, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/